

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Peter Collins et al.

Serial No.: 09/291,894

Filing Date: April 13, 1999



Group Art Unit: 1642

Examiner: B. Brumback

TECH CENTER 1600/2900

SEP 25 2001

RECEIVED

For: **PRODUCTION OF ATTENUATED CHIMERIC RESPIRATORY  
SYNCYTIAL VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES**

DATE OF DEPOSIT: September 17, 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS  
MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE  
AND IS ADDRESSED TO THE COMMISSIONER FOR PATENTS  
AND TRADEMARKS, WASHINGTON, DC 20231.

TYPED NAME: Jeffrey J. King  
REGISTRATION NO.: 38,518

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**AMENDMENT/RESPONSE**

In response to the Office Action mailed March 15, 2001, please amend the above-identified application as follows:

IN THE SPECIFICATION:

At page 1, following the heading "Related Applications", please delete the paragraph at lines 7-13 and replace it with the following paragraph that provides an amended priority claim in the application.

--The present application claims the priority benefit of, and is a continuation-in-part of, U.S. Patent Application No. 08/892,403, filed July 15, 1997, which is entitled to priority from U.S. Provisional Application No. 60/047,634, filed May 23, 1997, U.S. Provisional Application No. 60/046,141, filed May 9, 1997, and U.S. Provisional Application No. 60/021,773, filed July 15, 1996, each of which is incorporated herein by reference. The present application also claims the priority benefit of U.S. Patent Application No. 09/847,173, filed May 01, 2001, which is a divisional application of U.S. Patent Application No. 08/720,132, filed September 27, 1996, issued on July 24, 2001 as U.S. Patent No. 6,264,957, which is entitled to priority from U.S. Provisional Application No. 60/007,083, filed September 27, 1995, each of which is incorporated herein by reference.—